The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia

First-line nilotinib in chronic myeloid leukemia is more effective than imatinib to achieve early and deep molecular responses, despite poor tolerability or failure observed in one-third of patients. The toxicity and efficacy of tyrosine kinase inhibitors might depend on the activity of transmembran...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncotarget 2017-10, Vol.8 (50), p.88021-88033
Hauptverfasser:	Galimberti, Sara, Bucelli, Cristina, Arrigoni, Elena, Baratè, Claudia, Grassi, Susanna, Ricci, Federica, Guerrini, Francesca, Ciabatti, Elena, Fava, Carmen, D'Avolio, Antonio, Fontanelli, Giulia, Cambrin, Giovanna Rege, Isidori, Alessandro, Loscocco, Federica, Caocci, Giovanni, Greco, Marianna, Bocchia, Monica, Aprile, Lara, Gozzini, Antonella, Scappini, Barbara, Cattaneo, Daniele, Scortechini, Anna Rita, La Nasa, Giorgio, Bosi, Alberto, Leoni, Pietro, Danesi, Romano, Saglio, Giuseppe, Visani, Giuseppe, Cortelezzi, Agostino, Petrini, Mario, Iurlo, Alessandra, Di Paolo, Antonello
Format:	Artikel
Sprache:	eng
Schlagworte:	Research Paper
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!